Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 14, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DehydraTECH-CBD is protected by multiple patents in the USA and internationally and has received specific patent protection in both the EU and Australia for use in the treatment of heart disease.
Product Name : DehydraTECH-CBD
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin.
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Beta Glucan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The effect of oat beta glucan on the study primary endpoint is change in LDL-C, and some positive findings observed with different parameters, there were dosage-related responses in weight and body-mass index at 12 weeks but they also did not reach stat...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Beta Glucan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
Details : Algernon Pharmaceuticals has awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of AP-188 (“N,N-Dimethyltryptamine or DMT”), to Canadian-based Dalton Pharma Services.
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 19, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Algernon Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Psilocybine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Revive Therapeutics
Deal Size : $8.0 million
Deal Type : Acquisition
Revive Therapeutics Acquires Unique Psilocybin Assets
Details : All intellectual and work property derived from pre-clinical research activities from the National Health Research Institutes (“NHRI”) in traumatic brain injury and stroke, as it relates to psilocybin with the aim to obtain FDA Orphan Drug Designatio...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 17, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Revive Therapeutics
Deal Size : $8.0 million
Deal Type : Acquisition
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Algernon has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psi...
Product Name : AP-188
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 02, 2021
Lead Product(s) : Dimethyltryptamine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PP-001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Jiangsu Simcere Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Simcere Pharmaceutical Group and Primary Peptides Inc. Announce Exclusive China Partnership
Details : Simcere receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets.
Product Name : PP-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 05, 2020
Lead Product(s) : PP-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Jiangsu Simcere Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : PP-002
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Qingdao Primedicine Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the Partnership, Primedicine receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets. Financial terms were not disc...
Product Name : PP-002
Product Type : Peptide
Upfront Cash : Undisclosed
May 19, 2020
Lead Product(s) : PP-002
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Qingdao Primedicine Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement